Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA Closes Financing Round


InteRNA Technologies said this week that it has secured an undisclosed amount of equity financing, which it said would be used to develop its preclinical microRNA-based melanoma treatment.

The drug candidate is a mimic of miR-3157, which has been shown in vitro to inhibit proliferation and induce apoptosis in tumor cells. Last year, InteRNA CEO Roel Schaapveld told Gene Silencing News that the company aims to move the agent into human testing by the end of 2013 (GSN 10/25/2012).